Annals of Oncology


Advance Access published September 17,2014 doi:10.1093/annonc/mdu456 Everolimus plus exemestane for hormone-receptor- positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 M. Piccart, G. N. Hortobagyi, M. Campone, K. I. Pritchard, F. Lebrun, Y. Ito, S. Noguchi, A. Perez, H. S. Rugo, I. Deleu, H. A. Burris III, L. Provencher, P. Neven, M. Gnant, M. Shtivelband, C. Wu, J. Fan, W. Feng, T. Taran & J. Baselga

Great Clarendon Street Oxford OX2 6DP, UK Tel: +44 (0)1865 353827

corporate.services@oup.com www.annonc.oxfordjournals.org

Made with